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Abstract 
 
Checkpoint Inhibitors (CPI), namely anti-CTLA4 and anti-PD1/PD-L1 antibodies, demonstrated efficacy 
across multiple types of cancer. However, only subgroups of patients respond to these therapies. 
Additionally, CPI can induce severe immune-related adverse events (irAE). Biomarkers that predict 
efficacy and toxicity may help define the patients who may benefit the most from these costly and 
potentially toxic therapies. In this study, we review the main biomarkers that have been associated 
with the efficacy (pharmacodynamics and clinical benefit) and the toxicity (irAE) of CPIs in patients. 
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Key message 
 
Numerous biomarkers may reflect the pharmacodynamics of CPIs and predict their efficacy and/or 
their toxicity in patients. However, the use of these biomarkers in clinical practice remains ill-defined 
and will have to be clarified in future studies. Such biomarkers should help to define patients who will 
benefit most from these costly and potentially toxic drugs. 
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Introduction 
 
Checkpoint Inhibitors (CPI) are a new class of anti-cancer agents. These antibodies (Ab) target normal 
immune cells in order to stimulate the anti-tumor response. They work by blocking interactions 
between inhibitory receptors expressed on T cells and their ligands. In oncology, the two main classes 
of CPI which are the most advanced in clinical development are the anti-CTLA-4 and anti-PD-1/PD-L1 
Abs. Three of these Abs have been approved by the FDA for clinical use (Table 1). CPI can have 
efficacy across several types of cancer. However, only subgroups of patients respond to these drugs. 
Additionally, CPI can induce “autoimmune-like” toxicities. These findings raise several questions. 
What is the impact of CPI on the immune system? Are there biological markers related to their 
efficacy or toxicity? After a brief review of the mechanisms of action of CPI, we will present the 
biomarkers that have been associated with pharmacodynamics changes, therapeutic efficacy and 
toxicity of these treatments in clinic. 
 
CTLA-4 pathway 
 
T-cell activation following the stimulation of its receptor (T cell receptor [TCR]) requires a second 
signal which results from the interaction between the activating receptor CD28 located on the T cell 
surface and the CD80 (B7.1) and CD86 (B7.2) molecules expressed by the antigen-presenting cells 
(APC). Secondly, the activated T cell expresses CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) 
on its surface, an inhibitory receptor which also recognizes the CD80 and CD86 molecules, but with a 
much stronger affinity than CD28. The binding of CD80/CD86 to CTLA-4 then inhibits T cells. Anti-
CTLA-4 Abs block this interaction and prevent T cell inhibition1. They could also work by eliminating 
regulatory T cells (Tregs) that constitutively express this receptor2. 
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PD-1/PD-L1 pathway 
 
PD-1 or “programmed-death 1” is a surface protein which, once bound to its ligand, inhibits the 
proliferation and function of T cells. PD-1 receptor is expressed by T cells after activation. PD-1 
possesses two ligands, PD-L1 and PD-L2. PD-L1 is expressed on the surface of APC (mainly dendritic 
cells and macrophages) and a broad variety of tissues such as epithelial and endothelial tissues, in 
response to a stimulation by pro-inflammatory cytokines3. Expression of PD-L1 inhibits the 
proliferation of activated T cells and is responsible for negative feedback control of inflammation. The 
other PD-1 ligand, PD-L2, is expressed mainly by APC3. Expression of PD-L1 and/or PD-L2 by tumor 
cells or cells in the microenvironment allows the tumor to protect itself from the immune system. 
Blocking monoclonal Abs directed against PD-1 and PD-L1 have been developed in order to prevent 
PD-1/PD-L1 and PD-1/PD-L2 binding and so to restore the activity of anti-tumor T cells1. 
 
 
Biomarkers associated with pharmacodynamics and clinical responses to CPI 
 
The main biological markers associated with pharmacodynamics and/or clinical responses to CPI are 
listed in Table 2. A multitude of biomarkers has been studied, predominantly involving indices from 
the patient’s tumor (tumor cells or cells from the microenvironment) or blood (circulating cells or 
serum). The following section provides a brief summary of each biomarker most advanced in study. 
 
Circulating lymphocytes, neutrophils, eosinophils, and monocytes 
 
Several studies have shown that treatment with anti-CTLA-4 Ab increased the level of circulating 
lymphocytes4. This increase seems to be associated with a better clinical efficacy5–7. More recently, a 
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study conducted in a ‘real world’ population of melanoma patients treated with ipilimumab found a 
correlation between baseline absolute lymphocyte count (ALC) and overall survival (OS was greater in 
patients with increased ALC at baseline)8. 
Two studies evaluating an anti-PD-L1 Ab (MPDL3280A) in different cancers showed transient increase 
of CD8+ HLA-DR+ Ki-67+ cells early during treatment, but there was no correlation with clinical 
activity9,10. 
A study showed that the ratio between neutrophils and lymphocytes (N/L) during treatment with 
Ipilimumab correlated with clinical efficacy. A N/L ratio below normal limits after 7 and 10 weeks of 
treatment was significantly associated with a better survival11. 
A low level of eosinophils at baseline before treatment was associated with a better overall survival in 
patients treated with anti-CTLA-4 Ab (Ipilimumab) for a metastatic melanoma12. 
Finally, a high level of CD16-expressing monocytes at baseline was found to be associated with higher 
response rate and lower Tregs counts in the tumor microenvironment of responding patients13. 
 
CD4+ ICOShi T cells 
  
ICOS is a co-stimulatory receptor expressed on the surface of T cells after activation. In murine 
models, it has been shown that expression of ICOS is necessary for the efficacy of anti-CTLA-4 Ab. 
Indeed, mice lacking ICOS or its ligand have a lower response to anti-CTLA-4 Ab  than wild-type 
mice14. 
In patients, it has been described that anti-CTLA-4 Ab increased the number of CD4+ ICOShi T cells 
(producing IFNγ) in the blood15,16 and in the tumor16–18. For example, in patients receiving neo-
adjuvant therapy with anti-CTLA-4 Ab (Ipilimumab) for bladder cancer before cystoprostatectomy, 
CD4+ ICOShi T-Lymphocytes count was significantly increased in prostatic tissue, whether they were 
healthy or invaded by adenocarcinoma17. Moreover, a persistent increase of CD4+ ICOShi  T cells in 
blood after 12 weeks of treatment with anti-CTLA-4 Ab was associated with an improved clinical 
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outcome (defined as stable disease or objective response) and a better overall survival18.  
 
Diversity of T cell repertoire 
 
Anti-CTLA-4 therapy may amplify a pre-existing antitumor T cells response and/or generate T cells 
against new tumor antigens (“epitope spreading”). 
A retrospective study including 12 patients harbouring metastatic melanoma evaluated the diversity 
of the circulating T cell repertoire before treatment with anti-CTLA-4 Ab (Ipilimumab). In this study, 
response rate was higher in patients presenting with a more diverse T cell repertoire19. 
Cha et al. assessed TCR diversity during CTLA-4 blockade in patients with castration-resistant 
metastatic prostate cancer and metastatic melanoma, and found that clonotype stability after 
treatment was associated with a better clinical outcome20. 
Kvistborg et al. showed that anti-CTLA-4 therapy broadened the repertoire of melanoma-reactive 
CD8+ T cells but did not amplify pre-existing T cells. There was no correlation with clinical outcome21. 
In patients with metastatic melanoma, Tumeh et al found that clinical response to anti-PD1 therapy 
(pembrolizumab) correlated with i) a more clonal (i.e. more restricted, less diverse) TCR repertoire in 
pre-treatment tumor samples and ii) an increased clonal expansion of T cells in the tumor after anti-
PD1 therapy22. 
 
Immune response against tumor-associated antigens 
 
In patients with melanoma, the presence of Ab targeting NY-ESO-1 (a tumor antigen found in several 
solid tumors) before treatment and under treatment with Ipilimumab was associated with a better 
clinical outcome (defined as stable disease or partial/complete response)23. Among patients 
seropositive for NY-ESO-1, overall survival was higher in those harbouring CD8 T cells directed against 
NY-ESO-123. Interestingly, Kvistborg et al. demonstrated that anti–CTLA-4 treatment induced new 
7 
melanoma-specific CD8 T cells (in blood) but did not significantly expand melanoma-specific T cell 
responses that were already detected before start of therapy, suggesting that anti–CTLA-4 therapy 
enhances T cell priming21. 
Regulatory T cells (Tregs) 
 
Tregs express CTLA-4 constitutively and therefore can be targeted directly by anti-CTLA-4 Abs24. 
Studies have found a decrease in the number of circulating25 or intratumoral16,17 Tregs after 
Ipilimumab treatment while other studies did not find such depletion18,26,27. Data regarding the 
correlation between the variation of Tregs and clinical efficacy are likewise contradictory28–30. 
 
Myeloid-Derived Suppressor Cells (MDSCs) 
 
MDSCs are an heterogeneous population of cells that exists at basal state and expands under 
pathological conditions such as infection, inflammation or cancer, and exert suppressive activities, 
notably on T cells31. In certain types of cancer, circulating MDSCs have been found to correlate with 
tumor stage, tumor volume, and even prognosis32. A recent study by Martens et al. showed a 
correlation between a low baseline count of MDSCs and better overall survival in melanoma patients 
treated with anti-CTLA-433. Several studies found a decrease in the number of MDSCs following 
Ipilimumab therapy29,34. In one study, the decrease of certain types of MDSCs under Ipilimumab 
treatment (given in a neo-adjuvant setting) was associated with higher progression-free survival in 
patients with melanoma29. Similarly, Kitano et al. showed that a low monocytic MDSCs count at week 
6 after Ipilimumab treatment was associated with prolonged overall survival35. 
 
Soluble CD25 (sCD25) 
Anti-tumor activity of anti-CTLA-4 Ab seems highly dependent on IL-2, a cytokine involved in the 
activation of T cells. In murine models, neutralization of IL-2 or blockade of the α and β subunits of its 
8 
receptor (CD25 and CD122, respectively) precluded the anti-tumor effect as well as the increase in 
the ratio of intratumoral effector/regulatory T cells usually found during anti-CTLA-4 Ab therapy36. 
The soluble form of CD25 (sCD25), capable of capturing IL-2, decreases anti-CTLA-4 Ab efficacy in 
murine models36. In patients presenting with metastatic melanoma, a high level of sCD25 before 
treatment with Ipilimumab was associated with treatment resistance36. 
 
Cytokines/chemokines 
 
Treatment with anti-PD-L1 Ab (MPDL3280A) was associated with increased circulating IFN-γ, IL-18 
and ITAC (an IFN-γ inducible chemokine which is chemotactic for activated T cells) and decreased IL-
6. No correlation was found with clinical efficacy9,10. 
 
Lactate dehydrogenase (LDH) 
 
In some solid tumors and hematologic malignancies, a high level of LDH at baseline is frequently 
associated with poor prognosis. In advanced melanoma, the site(s) of metastasis and a high level of 
LDH at baseline are the two most significant prognostic factors37. Increased LDH at baseline seems to 
be associated with resistance to anti-CTLA-4 Ab therapy in advanced melanoma6,8,38. 
 
Tumor-infiltrating lymphocytes (TIL) 
 
The presence of lymphocytes within the tumor is a favorable prognostic factor in numerous 
cancers39. The lymphocyte infiltrate also seems to be a predictive factor of response to CPI. In 
patients with  metastatic melanoma treated with anti-CTLA-4 Ab (Ipilimumab), an increase in 
lymphocyte infiltrate in the tumor between baseline and at three weeks after treatment initiation 
correlated with clinical response40. Moreover, in melanoma patients treated with anti-PD-1 Ab 
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(Pembrolizumab), response rate was better in patients with high numbers of peri- and intra-tumoral 
CD8 T cells in their pre-treatment samples22. Analysis of biopsies after treatment with anti-CTLA-4 Ab 
(Ipilimumab) showed a correlation between a high ratio of intratumoral CD8/regulatory T cells and 
tumor necrosis16,41. Granzyme B is a cytotoxic granule reflective of CD8 effector function. In the 
tumor, its expression seems to be increased after anti-PD-142, anti-CTLA-440 or anti-PD-L1 Ab 
therapy9. Sample analysis from patients with metastatic melanoma obtained before and after anti-
PD-1 therapy showed a significant increase in granzyme B expressing CD8+ cells in post-dosing 
biopsies in the responding patients22. 
 
Mutational load 
 
CPI work by amplifying pre-existing anti-tumor responses. Several studies aimed to determine if 
“immunogenic” tumors, i.e. tumors that can be recognized by the immune system, were more 
sensitive to CPI. Immunogenicity is associated with the mutational load, in other words with the 
number of somatic mutations present in the tumor cells43. Indeed, the presence of mutations in the 
tumor generates neo-antigens (not expressed by normal cells) that are likely to be recognized by the 
immune system. The more mutations there are, the more the tumor is likely to be immunogenic.  
A study actually found a significant relationship between cytolytic activity in the tumor (defined by a 
greater perforin/granzyme B transcript level) and total mutation count in eight tumor types including 
colorectal and lung cancer44. Indeed, clinical studies showed that patients treated with anti-CTLA-4 Ab 
(Ipilimumab) for melanoma45,46 or with anti-PD-1 Ab (Pembrolizumab) for non-small cell lung 
carcinoma47 had  better clinical benefit if the mutational load of their tumor was high. Likewise, 
patients treated with anti-PD-1 Ab (Pembrolizumab) for colorectal cancer had a significantly better 
response rate and overall survival if they had a mismatch repair deficiency (involved in the repair of 
DNA replication errors)48. 
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PD-L1 expression within the tumor 
 
Given the mechanism of action of anti-PD-1 and anti-PD-L1 Abs, several studies have tried to 
determine if the efficacy of these Abs correlated with PD-L1 ligand expression in the tumor. The first 
studies provided evidence that there was indeed a strong link between PD-L1 expression by tumor 
cells and the response to anti-PD-1 Ab. Topalian et al. showed that all the responses to Nivolumab 
were observed in patients whose tumors expressed PD-L149. Likewise, in the KEYNOTE-001 trial, 
responses to Pembrolizumab correlated with PD-L1 expression by tumor cells50. A trial assessing the 
effect of an anti-PD-L1 (MPDL3280A) on different types of cancer found a correlation between the 
level of PD-L1 present in the intratumoral immune infiltrate (but not by the tumor cells themselves) 
and clinical response9. However, other studies did not confirm this correlation51–55. In a meta-analysis 
including 1475 patients treated with Nivolumab, Pembrolizumab or MPDL3280A, response rates were 
significantly higher in PD-L1 positive tumors (34% versus 19.9%)56.  
These differences regarding the predictive value of PD-L1 may have multiple explanations. First, the 
analysis of PD-L1 expression within tumors is not standardized. Different staining techniques are 
available, using different Abs for immunohistochemistry and different levels of positivity. Efforts are 
currently being made to harmonize the assessment of PD-ligand expression. Also, some studies 
looked at PD-L1 expression by tumor cells whereas others also included its expression by cells of the 
microenvironment. These differences could also be explained by the dynamic nature of PD-L1 
expression. In fact, PD-L1 is inducible, notably by IFN-γ exposure1. Therefore, a tumor which does not 
express PD-L1 at baseline may become PD-L1 positive in an inflammatory background. This could 
explain why basal expression of PD-L1 does not have a predictive value on response when anti-PD-1 
is combined with anti-CTLA-4 Ab in melanoma patients57. Inflammation induced by anti-CTLA-4 Abs 
could indeed induce PD-L1 in tumors formerly negative for this marker53. Lastly, a significant 
percentage of patients negative for PD-L1 respond to anti-PD-1/PD-L1 therapy. 
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Indoleamine 2,3-dioxygenase (IDO) 
 
IDO is an enzyme which degrades tryptophan, an essential amino-acid. Its presence lowers 
tryptophan availability in the tumor microenvironment and increases the concentration of its 
catabolite. IDO has an immunosuppressive effect by decreasing proliferation, function and survival of 
T cells58. Expression of IDO by some tumors contributes to immune escape. Hamid et al. found a 
positive correlation between a high expression of IDO at baseline and the clinical activity of 
Ipilimumab in metastatic melanoma40. The presence of IDO could indicate a pre-existing 
inflammatory/immune  response (IDO could be induced by pro-inflammatory cytokines like IFN-γ) 
which would promote the response to CPI59,60. 
 
Gene expression profile (GEP) 
 
In blood, transcriptome analysis has shown that treatment with an anti-CTLA-4 Ab induces a gene 
expression profile related to proliferation of T cells, mainly of memory phenotype61. Anti-PD-1 Abs are 
responsible for the expression of genes implicated in cytolysis and NK cell function61. Combination of 
anti-PD-1 and anti-CTLA-4 Abs induces higher gene expression compared to monotherapy, notably for 
genes involved in proliferation and coding of cytokines. Some genes can only be induced by the 
combination of both anti-PD-1 and anti-CTLA-4 Abs61. 
In the tumor, transcriptome analysis performed on biopsies from 45 patients with melanoma before 
treatment found gene expression profiles (increased expression of immunity-related genes) 
predictive of response to anti-CTLA-4 Ab (Ipilimumab) therapy62. Similarly, GEP performed in 
melanoma tumors before anti-PD1 treatment (pembrolizumab and nivolumab) revealed a 
transcriptional signature related to innate anti-PD-1 resistance (IPRES)63. Interestingly, IPRES 
signatures was not associated with resistance to anti-CTLA-4 suggesting that mechanisms of innate 
resistance to anti- PD-1 and anti-CTLA-4 may be different. 
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Melanoma patients responding to MPDL3280A (anti-PD-L1) had an increased expression of IFN-γ and 
IFN-γ-inducible genes (i.e. IDO1 and CXCL9) on pre-treatment tumours9. 
 
 
Biomarkers associated with toxicity of CPIs 
 
CPI, by stimulating the immune system non-specifically, can trigger side effects called Immune-
Related Adverse Events (irAEs). Most frequent irAEs may affect the skin (pruritus, rash, vitiligo), the 
intestinal tract (colitis), the liver (hepatitis) and the endocrine system. They are usually more 
pronounced with anti-CTLA-4 Abs than with anti-PD-1 or anti-PD-L1 Abs64. Notably, anti-CTLA-4 Abs 
can cause serious colitis. Some of these irAEs can be life-threatening. IrAEs may require 
discontinuation of CPI therapy and immunosuppressive treatment. Several studies looked for 
predictive biomarkers of toxicity. Main results are summarized in Table 3. 
 
Eosinophils 
 
In 156 patients presenting with metastatic melanoma, the circulating eosinophils count before and 
during treatment with anti-CTLA-4 Ab (Ipilimumab) was associated with irAEs occurence65. 
 
IL-17 
 
In 52 patients treated with anti-CTLA-4 Ab (Ipilimumab) for metastatic melanoma, increase followed 
by decrease of blood IL-17 levels were respectively associated with the settling and the resolution of 
colitis66. 
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Gene expression profile (GEP) 
 
Gene expression profiling performed on blood from patients treated with anti-CTLA-4 Ab 
(Ipilimumab) showed that, out of 10,000 probe sets tested, the increased expression of CD177 and 
CEACAM1 genes, two markers of neutrophil activation, was associated with digestive toxicity67. 
 
Digestive infiltrate by neutrophils 
 
A study of melanoma patients treated with anti-CTLA-4 Ab (Ipilimumab) showed that, on colon 
biopsies performed just before treatment initiation, lamina propria infiltration by neutrophils as well 
as other markers of inflammation (cryptic abscess, gland destruction, mucosal erosion) were 
associated with the occurrence of digestive toxicity68. 
 
Lastly, several studies suggest that the occurrence of irAEs could correlate with better efficacy of anti-
CTLA-4 Ab (Ipilimumab)25,69–71. However, association between toxicity and efficacy is not entirely 
clear72 and numerous patients respond to CPI therapy without experiencing irAEs. 
 
 
Conclusions 
 
Numerous biomarkers may reflect the pharmacodynamics of CPIs and predict their efficacy and/or 
their toxicity in patients. However, the relevance of these biomarkers to clinical practice and their 
potential for routine application remains ill-defined, and will have to be clarified in larger, prospective 
studies. A subset of biomarkers seem relevant and accessible enough to be part of our practices (e.g. 
LDH level, absolute lymphocytes count variation); others look promising but need standardisation of 
current practices (e.g. measure of PD-L1 expression) and finally, some biomarkers are not yet 
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accessible to daily practice (e.g. transcriptional analysis, mutational load). In addition, most of the 
biomarkers described so far have been tested in melanoma patients and therefore require validation 
in other cancer types and immunotherapeutic agents. 
Patients who seem to benefit most from CPIs are those presenting with immunogenic tumors (i.e. 
with a high mutational load), pre-existing immune response (intratumoral immune infiltrate) and the 
immune escape ligands being targeted (i.e. PD-L1 for patients treated with anti-PD-1/PD-L1 Abs). 
Nevertheless, these biomarkers are not perfect. In the future, better knowledge of the mechanisms 
of action of CPIs in vivo should help us identify other biomarkers in order to define patients who will 
benefit most from these effective but costly and potentially toxic drugs. 
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Table 1. CPIs FDA-approved for the treatment of cancer 
Target Antibody Isotype Company 
Indication (date of approval) 
Melanoma 
Non-small cell lung 
carcinoma 
Renal cell carcinoma 
CTLA-
4 
Ipilimumab IgG1 BMS 
• Unresectable or 
metastatic 
melanoma 
(2011) 
• Adjuvant 
treatment of 
patients with 
cutaneous 
melanoma with 
pathologic 
involvement of 
regional lymph 
nodes of more 
than 1 mm who 
have undergone 
complete 
resection, 
including total 
lymphadenecto
my (2015) 
• Patients with 
BRAF V600 wild-
type, 
unresectable or 
metastatic 
melanoma, in 
combination 
with nivolumab 
(2015) 
- - 
PD-1 Pembrolizumab IgG4 Merck 
• Unresectable or 
metastatic 
melanoma with 
disease 
progression 
following 
ipilimumab and, 
if BRAF V600 
mutation 
positive, a BRAF 
inhibitor (2014) 
• Initial treatment 
of patients with 
unresectable or 
metastatic 
melanoma 
• Metastatic non-
small cell lung 
cancer (NSCLC) 
whose tumors 
express 
programmed death 
ligand 1 (PD-L1) as 
determined by an 
FDA-approved test, 
with disease 
progression on or 
after platinum-
containing 
chemotherapy 
(2015) 
- 
   
  
(2015) 
Nivolumab IgG4 BMS 
• Unresectable or 
metastatic 
melanoma and 
disease 
progression 
following 
ipilimumab and, 
if BRAF V600 
mutation 
positive, a BRAF 
inhibitor (2014) 
• Patients with 
BRAF V600 wild-
type, 
unresectable or 
metastatic 
melanoma, in 
combination 
with ipilimumab 
(2015) 
• Metastatic non-
small cell lung 
cancer (NSCLC) with 
progression on or 
after platinum-
based 
chemotherapy.  Pati
ents with EGFR or 
ALK genomic tumor 
aberrations should 
have disease 
progression on FDA-
approved therapy 
for these 
aberrations prior to 
receiving nivolumab 
(2015) 
• Advanced 
renal cell 
carcinoma in 
patients who 
have 
received 
prior anti-
angiogenic 
therapy 
(2015) 
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Table 2. Biomarkers associated with pharmacodynamics and clinical response to CPI 
 
Biomarker Ab Result 
B
LO
O
D
 
Circulating 
lymphocytes, 
neutrophils 
eosinophils, and 
monocytes 
Anti-CTLA-
4 
 Increase of circulating lymphocytes count4 
 Increased lymphocytes count at baseline 
associated with better overall survival8 
 Increased lymphocytes count during treatment 
associated with better clinical efficacy5–7 
 Decreased neutrophils/lymphocytes ratio during 
treatment associated with higher survival 11 
 Low eosinophil baseline level associated with 
better survival12  
 High CD16-expressing monocyte level at baseline 
associated with higher response rate13 
Anti-PD-L1 
 Transient increase of CD8+ HLA-DR+ Ki-67+ 
lymphocytes9,10 
CD4+ ICOShi T cells 
Anti-CTLA-
4 
 Increase of CD4+ ICOShi  T cell count in blood, 
tumor and healthy tissues16–18 
 Persistent increase of circulating CD4+ ICOShi T cell 
count under treatment associated with better 
survival18 
Diversity of T cell 
repertoire 
Anti-CTLA-
4 
 Increase of TCR diversity20,21 
 Diversity of T cell repertoire associated with higher 
response rate19 
26 
Immune response 
against tumor-
antigens 
Anti-CTLA-
4 
 Presence of Ab directed against NY-ESO-1 antigen 
associated with higher clinical benefit in 
melanoma23 
 Presence of NY-ESO-1 specific T CD8 cells in NY-
ESO-1-seropositive patients associated with better 
survival in melanoma23 
Tregs  
Anti-CTLA-
4 
 Decrease of circulating Tregs count after 
Ipilimumab treatment in some studies25 
 Contradictory data concerning variation of 
circulating Tregs count and clinical response24–30 
MDSCs 
Anti-CTLA-
4 
 Decrease of MDSCs count upon Ipilimumab 
treatment29,34 
 Low baseline MDSCs count associated with better 
overall survival33 
 Decrease in several subtypes of MDSCs associated 
with higher progression-free survival29 
 Decrease in monocytic MDSCs during treatment 
associated with prolonged overall survival35 
Soluble CD25  
Anti-CTLA-
4 
 High basal serum level of soluble CD25 associated 
with treatment resistance36 
Cytokines/chemokines Anti-PD-L1 
 Increased level of IFN-γ, IL-18, ITAC and decreased 
level of IL-69,10 
LDH 
Anti-CTLA-
4 
 High basal serum level of LDH associated with 
treatment resistance6,8,38 
Gene expression Anti-CTLA-  Expression of genes involved in proliferation of T 
27 
profile 4 cells, mostly of memory subtype61 
Anti-PD-1 
 Expression of genes involved in cytolysis and NK 
cells proliferation61 
TU
M
O
R
 
Tumor-infiltrating 
lymphocytes (TIL) 
Anti-CTLA-
4 
 Presence of intratumoral lymphocytes associated 
with better clinical efficacy40  
 Increased CD4 T cells/Tregs ratio associated with 
tumor necrosis16,41 
 Increase of Granzyme B lymphocytes in the 
tumor after anti-CTLA-4 Ab40 
Anti-PD-1 
 Presence of peri- and intratumoral CD8 T cells 
associated with higher response rates22 
 Increase of granzyme B lymphocytes in the 
tumor after anti-PD-142 and anti-PD-L1 Ab9. 
 Increase in granzyme B CD8+ T cells after anti-
PD1 Ab associated with clinical efficacy in 
melanoma patients22. 
Diversity of T cell 
repertoire 
Anti-PD-1 
 More clonal (i.e. more restricted, less diverse) TCR 
repertoire in pre-treatment tumor samples 
associated with clinical response22 
 Increased clonal expansion of T cells after 
treatment associated with clinical response22 
Mutational load 
Anti-CTLA-
4 
 High mutational load associated with better 
efficacy in melanoma45,46 
Anti-PD-1 
 High mutational load associated with better 
efficacy in NSCLC47 
28 
 Mismatch-repair deficiency associated with better 
efficacy in CRC48 
PD-L1 
Anti-PD-1, 
anti-PD-L1 
 Intratumoral expression of PD-L1 associated with 
better clinical efficacy1,9,49–56 
IDO 
Anti-CTLA-
4 
 High IDO expression associated with better clinical 
efficacy40 
Gene expression 
profile 
Anti-CTLA-
4 
 Transcriptomic signature associated with better 
clinical efficacy in melanoma62,73 
Anti-PD-1 
 Transcriptomic signature associated with innate 
anti-PD-1 resistance (IPRES) in melanoma and 
other types of cancer63 
Anti-PD-L1 
 Increased IFN-γ genes expression on pre-
treatment tumor biopsies associated with 
response to anti-PDL1 in melanoma patients9 
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Table 3. Biomarkers associated with CPI toxicity 
 
 Biomarkers Drugs Association 
B
LO
O
D
 
Eosinophils Anti-CTLA-4 
 Increased eosinophils before and after treatment 
associated with irAEs occurence65 
IL-17 Anti-CTLA-4 
 Increased circulating IL-17 level during treatment 
associated with digestive toxicity66 
Gene expression 
profile 
Anti-CTLA-4 
 Increased expression of CD177 and CEACAM1 genes 
associated with digestive toxicity67  
TI
SS
U
E 
Digestive 
Neutrophils 
infiltrate 
Anti-CTLA-4 
 Infiltration of lamina propria by neutrophils in colon 
during treatment associated with digestive toxicity68 
 
 
